Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), one of the most-prescribed classes of medications worldwide, are indicated for the treatment of diabetes or obesity. A 2024 epidemiologic study by Hathaway and colleagues showed that these drugs can increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION) by 4-fold among patients with diabetes and by 7.6-fold among overweight patients with previous type 2 diabetes (T2D).
Visionary News & Insightful Strategy
Footer
A RETINA-SPECIFIC ORGANIZATION
It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.
We’ve got our eyes on working with the best retina groups and vendors in the industry.
See the best; get in touch.
Recent
- VIDEO: Tecnis Odyssey IOL provides full visual range at all distances, lighting
- Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
- AI Optics’ portable Sentinel Camera gains FDA 510(k) clearance
- Decentralized clinical trials: FDA guidance and the ‘new modus operandi’
- GLP-1 RAs and Nonarteritic Anterior Ischemic Optic Neuropathy
Leave a Reply